

Ticker: MLSS
 Exchange:OTCBB/OTCQB
 Share price (as of 5/09/12):\$0.45
 Common shares outstanding: 15.7 M
 Market capitalization: 7.1 M
 Revenue 2011: \$8.4 M
 Net income 2011:..... (\$1.4 M)
 Total Shareholders' Equity (12/31/11):..... \$1.9 M
 Fiscal year-end: December 31
 Security Ownership of Mngmt:22.4%

* At December 31, 2011, Milestone had outstanding options and warrants to purchase \$1.8M shares of common stock at prices ranging from \$0.32 to \$2.69 per share with a weighted average exercise price of \$1.13.

About Milestone Scientific

Milestone Scientific has developed a patented and FDA approved painless injection system for the dental and medical markets. It is the first major breakthrough in injection technology since the invention of the hypodermic needle. By using pressure sensing technology, Milestone enables dentists and healthcare practitioners to administer pain-free injections by controlling the flow rate of the fluid being injected. The company has 24 issued patents and has won a number of awards over the past three years in the dental community, where Milestone currently derives its revenue. There are extensive opportunities for the company to broaden its market to include medical applications, such as epidurals, osteoarthritis, self-administered applications such as diabetes, multiple sclerosis and rheumatoid arthritis. Cosmetic surgery, ophthalmic surgery and neurosurgical injections are other potential applications.



Investment Highlights

- ✓ Conventional needle syringes present challenges for patients and doctors
- ✓ Patented and FDA approved painless injection system
- ✓ Established track record and broad industry recognition
- ✓ **New sales and marketing strategy targeting large dental groups**
- ✓ High margin recurring revenue model from disposable handpieces
- ✓ Opportunity to expand into new injection applications
- ✓ Highly scalable business utilizing outsourced production model

Company Profile

- Proprietary computer-controlled injection technologies targeting the medical and dental markets
- First major breakthrough in injection technology since invention of hypodermic syringes
- Precision, painless injections for all dental treatments
 - Root canals, crowns, fillings, cleanings, etc.
 - Over 44 million injections administered to date
- Award-winning products
- Global distribution network
 - North and South America, Asia, Africa and Europe
 - IP portfolio consists of 24 issued patents

Single Tooth Anesthesia (STA) System

- Introduced in February 2007 and incorporates CompuFlo® technology
- Allows dentists to administer injections accurately and painlessly into the periodontal ligament space, effectively anesthetizing a single tooth
- Anesthetizes the tooth within one or two minutes versus 8-18 minutes for a block injection
 - No pain or collateral anesthesia in the cheek, lips or tongue
- Capable of performing all injections done with a conventional syringe



Core CompuFlo® Technology

- Regulates and controls flow rate of fluid
- Dynamic Pressure Sensing® capability provides visual and audible in-tissue pressure feedback
 - Ability to identify tissue types and inject drugs at the precise location
 - Minimizes tissue damage and eliminates pain of the injection because the flow rate and pressure of the injection are controlled
- Disposable injection handpiece that provides for precise tactile control during the injection
- Ability to record data from the injection event



New Sales & Market Strategy

- Refocused sales strategy implemented in 2010
 - Reduced reliance on third party distributors
 - Marketing directly to group practices
- Expanded internal sales force & customer support
 - Hired director of international sales and director of domestic sales
 - Utilizing independent hygienists to train and support group dental practices
- Signed on first group dental practice in January 2011—Towncare Dental
 - 27 offices throughout central and south Florida
 - The STA Instrument will replace the syringe in these practices

Industry Recognition

Favorably evaluated in more than 50 peer reviewed and independent clinical research reports




Non-Dental/Medical Applications

- **Over 700 applications** outside the dental industry
- Unique ability to identify the tissue in which the needle tip is imbedded
 - Epidural, intra-articular, organ, subcutaneous and intramuscular injections
- Medical procedures requiring intravenous sedation can be performed with local anesthesia due to pain reduction
 - Local anesthetic reduced thereby minimizing side effects, accelerating recovery times, lowering costs and eliminating potential complications
- Clinical evidence demonstrating benefits in epidurals, intra-articular injections, colorectal surgery, podiatry, dermatology, nasal/sinus surgery, hair transplant and cosmetic surgery
- New products **subject to 510(k) submission**, reducing development cost and time to market

Near-Term Application: Epidural

- 2.5 million U.S. women who give birth each year receive epidurals
 - Represents approximate \$1 billion annual U.S. market
 - Doctors using conventional syringes identify the epidural space by relying on subjective perception
- Potential complications with conventional standard of care
 - Paraplegia (1 in 250,000)
 - Wet Tap (1 in 30)
 - Dural Puncture (1 in 100)
 - Death (less than 1 in 100,000)
 - Catheter Misplaced into Vein (1 in 300)
 - Neurological Injury > one year (1 in 6,700)
 - Neurological Injury < one year (1 in 240,000)
 - Epidural Abscess or Hematoma (1 in 150,000)
- CompuFlo® consistently and accurately identifies the epidural space
 - Detects the difference in pressure between the ligamentum flavum and the extraligamentary tissue
 - In studies, epidural space has been correctly identified 100% of the time



New Product Introduction Strategy

- Plan to JV with third party medical device manufacturers and distributors
 - Partners cover upfront commercialization costs
 - Receive exclusive product license
- Over **70 unique injection instruments** and 240 unique disposables identified and available
- Recently established joint venture to develop intra-articular and epidural drug delivery instruments utilizing CompuFlo technology



Joint Venture

- Formed medical joint venture with Beijing 3H (Heart-Help-Health) Scientific Technology in July 2011
- First two products under development are epidural and intra-articular injections
- 50/50 arrangement between Beijing 3H and Milestone Scientific
- Milestone to provide exclusive worldwide royalty-free license for use of its patents
- To date, Beijing 3H has contributed \$1.5 million to the medical joint venture

For Additional Information

Investor Contact:
David K. Waldman
Crescendo Communications, LLC
(212) 671-1020
mlss@crescendo-ir.com

The information contained herein was obtained from Milestone Scientific and other sources Crescendo Communications, LLC believes to be reliable. This does not constitute the solicitation of the purchase or sale of securities. Crescendo is employed by the Company as its investor relations firm. Except for the historical information contained herein, the matters discussed in this document are forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Certain of these risks and uncertainties will be described in greater detail in Milestone Scientific's filings with the Securities and Exchange Commission.